Article

Zyloware to produce Randy Jackson Eyewear

Long Island City, NY-Zyloware Corp. has signed a license agreement to manufacture, market, and distribute Randy Jackson Eyewear. The new brand is scheduled to reach the market by January 2008.

Long Island City, NY-Zyloware Corp. has signed a license agreement to manufacture, market, and distribute Randy Jackson Eyewear. The new brand is scheduled to reach the market by January 2008.

Jackson, most visible for his stint as one of three principal judges on the hit "American Idol" TV series, has a music industry career that spans more than 20 years. He played bass in the band Journey during the 1980s and then went on to produce numerous Grammy Award-winning albums. A keen eye for talent led Jackson to positions of increasing responsibility, first with Columbia Records and later MCA Records.

"If you need eyewear or just want to be very cool and fashionable, these are the only glasses you will be wearing," said Jackson.

Zyloware's Chris Shyer said, "Randy Jackson has a remarkable 'sixth sense' for success. He represents high energy and good values. He embodies excellent taste and is a true gentleman in everything he does. There isn't a better person to represent America's next brand of eyewear."

For more information on Randy Jackson Eyewear, contact Zyloware at 800/765-3700, by e-mail info@zyloware.com
, or online at http://www.randyjacksoneyewear.com/.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.